Abstract

Dr. Tarun Surya Sai Amaresh Ravula*, Dr. S. Uma Sankar, Dr. U. V. Sai Srinivas, Dr. Soumya Puranam, Dr. Akshay Tiruvedula and Dr. P. Seetaramaiah

ABSTRACT

Introduction: The co-administration of PPIs and psychiatric drugs for the treatment of stress-induced erosive gastropathy has not received much attention. In order to close this knowledge gap, our study offers proof of the effectiveness and security of this kind of combination therapy. This study intends to improve patient outcomes, lessen the intensity of symptoms, and improve the quality of life for those with SIEG by treating both the physiological and psychosocial elements of the illness. Finding the best treatment plan can be accomplished by contrasting the results of rabeprazole monotherapy with rabeprazole in combination with flupentixol/melitracen. A deeper comprehension of various therapy methods may result in enhanced patient care, improved management techniques, and maybe lower medical expenses through more efficient care. Methods and Material: This was a observational cohort study conducted on 54 students at at Lalitha super specialties hospital, Guntur. Patients who visited the LSSH departments of general & minimally invasive surgery, general medicine (gastroenterology), and met the study requirements were included. Numerical pain rating was used to assess the change in pain after treatment, DASS21 scale was used to assess the change in stress after treatment , dyspnoea symptoms and adverse events were also assessed. Results: There are 32 male and 22 female patients total in the research. 46 patients in all had NPRS decreases, of which 85.71% were attributable to combination treatment and 84.61% to monotherapy. 40 patients in all had reduced stress levels; of these, 85.71% were attributable to combination treatment and 61.53% to monotherapy. 23 individuals in all had reduced dyspepsia symptoms, of which 46.42% were brought on by combination medication and 38.46% by monotherapy. More number of adverse events were found in patients treated with combination therapy. Conclusion: In summary, the combination of rabeprazole and flupentixol/melitracen is more successful in treating SIEG than rabeprazole monotherapy, even if it is still a safe alternative. To improve patient outcomes, clinicians should take into account this combination therapy, especially when stress and psychological variables are major contributors to the illness process.